Recent Activity

Loading...

SVRA

Savara, Inc. · NASDAQ

Performance

-11.64%

1W

-13.18%

1M

-9.86%

3M

+24.27%

6M

-4.68%

YTD

+80.65%

1Y

Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.

Investment Analysis Report: SVRA

Overview:

SVRA is a pharmaceutical company operating in the Health Technology sector with a market capitalization of $672.64 million. The company's financial data over the past three years provides insights into its valuation, financial health, earnings and revenue growth, profitability, operating margin, operati...

See more ...

Technical Analysis of SVRA 2024-05-10

Overview:

In analyzing the technical indicators for SVRA over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive assessment of the stock's potential price movement. By examining these key factors, we aim to offer valuable insights and predictions for the next few days.

Trend Anal...

See more ...

Recent News & Updates